Ms Karolina Faysman on Assessing the Signs and Symptoms of cGVHD Overall Response Rate, Including by Grade and Organ
Data from REACH2 are not included in the FDA-approved Prescribing Information for Jakafi. FDA approval for Jakafi for the treatment of steroid-refractory aGVHD was based on data from the REACH1 study.
Ms Karolina Faysman on Assessing the Signs and Symptoms of cGVHD
REACH, Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation.